Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter, single-arm, open-label, long-term safety study of macitentan in pulmonary arterial hypertension
2017-003934-10Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Long-term safety of macitentan 10 mg. Started Jan 2018; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2017-003934-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003934-10.